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Standard chemotherapyObjective/background: To study whether interleukin (IL)-10 gene polymorphism is associated
with multi-drug resistant tuberculosis (MDR TB) during the intensive phase of standard
chemotherapy.
Methods: The study comprised 170 individuals in Kharkiv region of Ukraine including 74
patients with pulmonary MDR TB (Group 1), 66 patients without MDR TB (Group 2), and
30 healthy donors (Group 3). Serum level of IL-10 was evaluated by enzyme-linked
immunosorbent assay (pg/L). Measurements of serum samples were conducted before or
during the initial days after hospital admission and after 2 months on antituberculous ther-
apy. Investigations of IL-10 gene polymorphism were performed using restriction analysis
of the amplification products of specific regions of the genome. The method of investiga-
tion (for the sets real-time) — an allele-specific PCR using intercalating coloring Sybr Green.
Polymorphism G1082A of gene IL-10 rs1800896 were genotyped with amplification-
refractory mutation system-polymerase chain reaction.
Results: In Group 1, the level of IL-10 was (38.01 ± 0.78) pg/L, compared with 43.88 ± 0.70 in
Group 2, and 50.25 ± 1.26 in Group 3 (p < 0.05 among the groups). In Group 1, 56 (75.68
± 4.99%) patients had heterozygote GA genotype, 11 (14.86 ± 4.14%) patients had homozy-
gote AA genotype, and seven (9.46 ± 3.40%) patients had homozygote GG genotype. In
Group 2, 41 (62.12 ± 5.97%) patients had homozygote AA genotype, 17 (25.76 ± 5.38%)
patients had heterozygote GA genotype, and eight (12.12 ± 4.02%) patients had homozygote
GG genotype. In Group 3, 17 (56.67 ± 9.05%) healthy donors had homozygote GG genotype,
seven (23.33 ± 7.72%) healthy donors had heterozygote GA genotype, and six (20.0 ± 7.30%)
healthy donors had homozygote AA genotype (p < 0.05 among the groups). Following
2 months antituberculous therapy treatment, there was a significant increase in IL-10 levels
in Group 1 (44.58 ± 0.78) and Group 2 (50.59 ± 0.99; p < 0.05 between the groups), when com-
pared to the beginning of therapy and after 2 months (p < 0.001).
Conclusion: Compared to the healthy control group, patients with TB had significantly lower
levels of IL-10. This coincided with a greater frequency of heterozygote GA genotype in
Group 1 and homozygote AA genotype in Group 2. Further studies are warranted to deter-y Avenue,
during the
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intensive phase of standard chemotherapy. Int.mine whether a higher number of patients without MDR TB have a causal immunogenetic
relationship with IL-10 gene polymorphisms than patients with MDR TB. Standard 2-month
TB therapy results in reversal of inflammation characterized by increased IL-10 to a level
comparable to that in healthy donors. IL-10 is an immune correlate of treatment outcome
and can help to identify a better strategy for TB management. TB chemotherapy may have
an immunomodulatory effect of an anti-inflammatory nature.Conflicts of interest
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